DDIT3 and follicular lymphoma: These examinations corresponded to a 36-year old obese female patient assessed for a Hodgkin lymphoma who received R-BAC (Rituximab-Bendamustine/Aracytine/Cytarabine) as third-line of treatment (patient #108) and a 53-year old overweight male patient assessed for a follicular lymphoma who received R-CHOP as second-line of treatment (patient #146).